Table 1.
Features of patients with TAO and normal controls undergoing surgery.
| TAO | NC | p | |
|---|---|---|---|
| No. of participants | 15 | 10 | |
| Sex, M/F | 9/6 | 3/7 | 0.2262 |
| Age, mean ± SD, (range), y |
47.47 ± 7.846 (34–61) |
43.00 ± 13.44 (28–70) |
0.3120 |
| Clinical activity score | NA | ||
| Stable | 8 | ||
| Active | 7 | ||
| Duration of TAO, median (range), m |
28 (2–98) | NA | |
| Therapy history | NA | ||
| Thyroid surgery | 1/15 | ||
| Orbital irradiation | 2/15 | ||
| Steroid treatment | 5/15 | ||
| Thyroid function | NA | ||
| Hyperthyroid | 1/15 | ||
| Hypothyroid | 0/15 | ||
| Euthyroid | 14/15 |
TAO, Thyroid-associated ophthalmopathy; NC, normal control; M, male; F, female; SD, standard deviation; y, year; m, month; NA, not applicable.